News and events
- All
- Events
- Press releases
- Publications
All
- All
- Events
- Press releases
- Publications
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
xeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing ...
January 9, 2023
Read More
Bio Partnering at JPM — January 9-12, 2023 – San Francisco, CA
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit ...
January 5, 2023
Read More
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors. Dr. Bolger has over 35 years ...
October 20, 2022
Read More
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a ...
September 1, 2021
Read More
ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a ...
August 18, 2021
Read More